Ebola update received via email distribution: N
Post# of 9144
Posted On: 03/01/2015 5:44:13 PM
Ebola update received via email distribution:
NanoLogix is pleased to announce that the Company, along with two of the world's leading biomedical research institutions as partners, has applied for funding from the Defense Threat Reduction Agency (DTRA), part of the U.S. Department of Defense, for further development of its N-Assay diagnostic for the Ebola virus.
This application was made under DTRA Proposal No: EBOLA-CBA-01-1-0165, Title: Diagnostics, Topic: CBA-01. Following the security and confidentiality requirements of DTRA, any further information will remain confidential until released by DTRA.
NanoLogix advises those interested that there is no guarantee of funding for any application made. The application was submitted after preliminary research by a separate group demonstrated valid proof of concept for rapid detection and identification of EBOV utilizing the N-Assay-V.
For further information on the ongoing efforts by the Department of Defense and DTRA on biological threats, you may follow the following links:
http://www.defense.gov/news/newsarticle.aspx?id=128260
https://www.youtube.com/watch?v=0qB_vjATKS0
DTRA is the U.S. Department of Defense’s official Combat Support Agency for countering weapons of mass destruction.
These links are provided as a public service for information and reference only and should not be construed in any way as an endorsement of NanoLogix by the DoD or DTRA.
NanoLogix is pleased to announce that the Company, along with two of the world's leading biomedical research institutions as partners, has applied for funding from the Defense Threat Reduction Agency (DTRA), part of the U.S. Department of Defense, for further development of its N-Assay diagnostic for the Ebola virus.
This application was made under DTRA Proposal No: EBOLA-CBA-01-1-0165, Title: Diagnostics, Topic: CBA-01. Following the security and confidentiality requirements of DTRA, any further information will remain confidential until released by DTRA.
NanoLogix advises those interested that there is no guarantee of funding for any application made. The application was submitted after preliminary research by a separate group demonstrated valid proof of concept for rapid detection and identification of EBOV utilizing the N-Assay-V.
For further information on the ongoing efforts by the Department of Defense and DTRA on biological threats, you may follow the following links:
http://www.defense.gov/news/newsarticle.aspx?id=128260
https://www.youtube.com/watch?v=0qB_vjATKS0
DTRA is the U.S. Department of Defense’s official Combat Support Agency for countering weapons of mass destruction.
These links are provided as a public service for information and reference only and should not be construed in any way as an endorsement of NanoLogix by the DoD or DTRA.
(0)
(0)